Professor Ye Xiongjun: From Systemic Therapy to Minimally Invasive Surgery — What “Surprises” Await in Kidney Cancer Treatment?

Professor Ye Xiongjun: From Systemic Therapy to Minimally Invasive Surgery — What “Surprises” Await in Kidney Cancer Treatment?

2025.11.19
In recent years, the incidence of urological malignancies in China has risen steadily. Prostate, bladder, and kidney cancers now rank among the most common malignancies in the country, posing a serious threat to public health. The Department of Urology at the National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences (CICAMS), has long been dedicated to the diagnosis and treatment of urological tumors. With extensive experience in laparoscopic and minimally invasive surgery as well as multidisciplinary cancer management, it stands as a leading force in China’s field of urologic oncology.
NCCU 2025 | Professor Yong Zhang Explains the Advantages, Beneficiaries, and Learning Path of the “Xing’s Neobladder” Technique

NCCU 2025 | Professor Yong Zhang Explains the Advantages, Beneficiaries, and Learning Path of the “Xing’s Neobladder” Technique

2025.11.18
Bladder cancer is one of the most common malignancies of the urinary system. Radical cystectomy remains one of the standard treatments, and urinary diversion is a crucial component of this complex procedure.Professor Xing Nianzeng and his team pioneered a novel laparoscopic-friendly orthotopic ileal neobladder reconstruction technique, known as the “Xing’s Neobladder.” This innovative approach utilizes a detubularized ileal segment to construct a spherical, orthotopic ileal neobladder with two peristaltic input loops, preventing urinary reflux and avoiding excessive tension or compression on the left ureter. The design helps preserve upper urinary tract function while ensuring physiological urine flow.During the National Cancer Center Urological Oncology Conference & Medical Frontier Forum (NCCU 2025), Oncology Frontier – Urology Frontier invited Professor  Yong Zhang from the National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, to share his insights on this groundbreaking technique.
Navigating Global Access, Regulatory Harmonization, and Future Directions in CAR-T Cell Therapy: Insights from a Global Panel Discussion

Navigating Global Access, Regulatory Harmonization, and Future Directions in CAR-T Cell Therapy: Insights from a Global Panel Discussion

2025.11.18
The Cellular Therapy and Immunotherapy Conference 2025 was successfully held in Hangzhou, China, from November 13-16, 2025. The conference brought together a distinguished gathering of the world's leading researchers, clinicians, and industry pioneers to share groundbreaking advancements and foster collaboration in the rapidly advancing fields of cellular and immune-based treatments. The morning's agenda offered a comprehensive survey of the global landscape, featuring in-depth presentations on the evolution of CAR-T cell therapies in China, Europe, and Japan. The discussions also addressed critical challenges in navigating regulatory frameworks, ensuring patient access, and maintaining affordability for cell and gene therapies across diverse regions, including Asia, Latin America, and other resource-limited settings. Culminating these insightful sessions was a dynamic Panel Discussion. This concluding segment provided a vital forum for the session's international experts to synthesize the diverse perspectives shared, engage in a robust dialogue on overcoming current obstacles, and collaboratively envision the future trajectory of immunotherapy and cell therapy on a global scale. The discussion underscored a collective commitment to advancing these transformative treatments from the laboratory to patients in need worldwide.
FACO China–Japan Expert Dialogue | Professors Jin Li, Xiaotian Zhang, and Koji Kono Discuss Precision Treatment Advances in HER2-Positive Gastric Cancer

FACO China–Japan Expert Dialogue | Professors Jin Li, Xiaotian Zhang, and Koji Kono Discuss Precision Treatment Advances in HER2-Positive Gastric Cancer

2025.11.13
China, Japan, and other Asian countries have some of the highest rates of gastric cancer worldwide. In China, the majority of patients are still diagnosed at an advanced stage, having already lost the opportunity for curative surgery. Effective systemic therapy is therefore essential for improving survival. In recent years, innovative drugs represented by antibody–drug conjugates (ADCs)—such as the HER2-targeted ADC trastuzumab deruxtecan (T-DXd)—have achieved major breakthroughs in pivotal clinical studies including DESTINY-Gastric04. These advances are expected to gradually transform the treatment landscape starting from later lines of therapy. Asian clinical researchers have played an important role in these studies, contributing insights that are redefining clinical practice.